Stay Connected
Join us on Facebook Follow us on linked in Follow us on YouTube Follow us on Vimeo
cardiovascular CRO experts, experience and execution
Cardiovascular Clinical Research

Learn more


Medpace is a full and active member of the Cardiac Safety Research Consortium. The Cardiac Safety Research Consortium (CSRC) was launched in 2006 through a MOU with Duke University to support research into the evaluation of cardiac safety of medical products. CSRC supports research by engaging stakeholders from industry, academia, and government to share data and expertise. Outputs of the CSRC include research projects taking advantage of waveforms released from the FDA ECG warehouse, “Think Tank Incubator” programs, and consensus white papers.

Cardiovascular CRO for Clinical Research

Medpace cardiovascular teams are well-versed in the scientific methodology, standard of care, evolving regulatory requirements and operational considerations necessary to effectively bring to market drugs and devices that treat or prevent heart disease. Our extensive experience in cardiovascular studies and consistent track record of success in the industry ensures the flexibility to adapt to the unique needs of each cardiovascular trial. We help our clients:

  • Effectively plan and conduct cardiovascular, drug/device combination and cardiac safety studies
  • Efficiently conduct large cardiovascular endpoint trials that demand rigorous safety requirements
  • Seamlessly integrate cardiovascular trials with metabolic/endocrinology projects

Deep and Broad Cardiovascular Experience

  • Since 1992, Medpace has conducted hundreds of Phase I-IV cardiovascular drug and device trials, involving patients in nearly 50 countries
  • Contributed to numerous cardiovascular NDAs and helped pioneer many of the preventative cardiovascular compounds and devices introduced in the last 15 years
  • Includes studies in acute care settings, drug/device combination studies, large outcome studies, thorough QT studies and managing Clinical Endpoint Committees (CEC) and adjudication processes for numerous studies

The Medpace Difference for Cardiovascular Studies

In addition to the Medpace Difference that applies to all of our therapeutic areas, our cardiovascular Sponsors benefit from:
  • Board-certified cardiologists with backgrounds in academic clinical practice and pharmaceutical development, one of whom designed and managed the largest coronary trial to date. Medpace is a member of the Scientific Oversight Committee of the Cardiac Safety Research Consortium, a joint collaboration with the FDA, academia and industry.
  • Operational and regulatory teams that have significant global experience in both drug and device studies, making them well-suited for the complex nature of cardiovascular trials.
  • ECG Core Laboratory to provide sponsors with reliable, consistent, and prompt electrocardiographic services and manage the rigors of cardiac safety studies, including thorough QT.
  • Medpace Medical Device, exclusively dedicated to the design and conduct of medical device trials.